Literature DB >> 30006253

The affinity of antipsychotic drugs to dopamine and serotonin 5-HT2 receptors determines their effects on prefrontal-striatal functional connectivity.

F Tollens1, N Gass1, R Becker1, A J Schwarz2, C Risterucci3, B Künnecke3, P Lebhardt1, J Reinwald4, M Sack1, W Weber-Fahr1, A Meyer-Lindenberg5, A Sartorius6.   

Abstract

One of the major challenges of cross-species translation in psychiatry is the identification of quantifiable brain phenotypes linked to drug efficacy and/or side effects. A measure that has received increasing interest is the effect of antipsychotic drugs on resting-state functional connectivity (FC) in magnetic resonance imaging. However, quantitative comparisons of antipsychotic drug-induced alterations of FC patterns are missing. Consideration of receptor binding affinities provides a means for the effects of antipsychotic drugs on extended brain networks to be related directly to their molecular mechanism of action. Therefore, we examined the relationship between the affinities of three second-generation antipsychotics (amisulpride, risperidone and olanzapine) to dopamine and serotonin receptors and FC patterns related to the prefrontal cortex (PFC) and striatum in Sprague-Dawley rats. FC of the relevant regions was quantified by correlation coefficients and local network properties. Each drug group (32 animals per group) was subdivided into three dose groups and a vehicle control group. A linear relationship was discovered for the mid-dose of antipsychotic compounds, with stronger affinity to serotonin 5-HT2A, 5-HT2C and 5-HT1A receptors and decreased affinity to D3 receptors associated with increased prefrontal-striatal FC (p = 0.0004, r² = 0.46; p = 0.004, r² = 0.33; p = 0.002, r² = 0.37; p = 0.02, r² = 0.22, respectively). Interestingly, no correlation was observed for the low and high dose groups, and for D2 receptors. Our results indicate that drug-induced FC patterns may be linked to antipsychotic mechanism of action on the molecular level and suggest the technique's value for drug development, especially if our results are extended to a larger number of antipsychotics.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Antipsychotic agents; Dopamine antagonists; Magnetic resonance imaging; Psychotic disorders; Schizophrenia; Serotonin antagonists

Mesh:

Substances:

Year:  2018        PMID: 30006253     DOI: 10.1016/j.euroneuro.2018.05.016

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  5 in total

1.  Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia.

Authors:  Xuan Wang; Meihong Xiu; Keqiang Wang; Xiuru Su; Xirong Li; Fengchun Wu
Journal:  Metabolomics       Date:  2022-07-11       Impact factor: 4.747

2.  Treatment Effect of Long-Term Antipsychotics on Default-Mode Network Dysfunction in Drug-Naïve Patients With First-Episode Schizophrenia: A Longitudinal Study.

Authors:  Mengjie Deng; Zhening Liu; Yanyu Shen; Hengyi Cao; Manqi Zhang; Chang Xi; Wen Zhang; Wenjian Tan; Jinqiang Zhang; Eric Chen; Edwin Lee; Weidan Pu
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

3.  Effect of Risperidone Monotherapy on Dynamic Functional Connectivity of Insular Subdivisions in Treatment-Naive, First-Episode Schizophrenia.

Authors:  Xujun Duan; Maolin Hu; Xinyue Huang; Chan Su; Xiaofen Zong; Xia Dong; Changchun He; Jinming Xiao; Haoru Li; Jinsong Tang; Xiaogang Chen; Huafu Chen
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

Review 4.  Systematic Review on Parkinson's Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson's Symptoms.

Authors:  Palanisamy Sivanandy; Tan Choo Leey; Tan Chi Xiang; Tan Chi Ling; Sean Ang Wey Han; Samantha Lia Anak Semilan; Phoon Kok Hong
Journal:  Int J Environ Res Public Health       Date:  2021-12-30       Impact factor: 3.390

5.  Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia.

Authors:  Herbert Y Meltzer; Daniel B Share; Karu Jayathilake; Ronald M Salomon; Myung A Lee
Journal:  J Clin Psychopharmacol       Date:  2020 May-Jun       Impact factor: 3.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.